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Abstract
This paper describes an initial dataset and automatic natural language processing (NLP) method for extracting con-
cepts related to precision oncology from biomedical research articles. We extract five concept types: CANCER, MU-
TATION, POPULATION, TREATMENT, OUTCOME. A corpus of 250 biomedical abstracts were annotated with these
concepts following standard double-annotation procedures. We then experiment with BERT-based models for concept
extraction. The best-performing model achieved a precision of 63.8%, a recall of 71.9%, and an F1 of 67.1. Finally,
we propose additional directions for research for improving extraction performance and utilizing the NLP system in
downstream precision oncology applications.
1 Introduction
Precision medicine is a paradigm in which treatment decisions are based not just on a patient’s disease status, but
on a variety of other factors including specific genetic, environmental, and other factors. [1] The preeminent use case
for precision medicine thus far has been cancer, i.e. precision oncology. Precision oncology is a rapidly-developing
field [2], with a growing number of treatments, trials, and genomic markers. Since drugs can be targeted to relatively
rare mutations, the number of studied treatments is greatly expanded [3,4] and these can be referred to by a variety of
names (e.g., the name used in pre-clinical trials is often different than the final drug name). Since the gene mutations
can be relatively rare, clinical trial structures have had to be altered to better fit the precision medicine paradigm. [5]
And, critically, there are thousands of known genetic mutations from hundreds of cancer-related genes. [6] Sizable
effort is thus required to curate all of these types of information to make them available in a usable form to both
researchers and clinicians.
Our prior work has focused on this problem from an information retrieval (IR) perspective: how does one find patient-
specific information (given a type of cancer, mutation, etc.) from the vast trove of precision medicine-related pub-
lications. IR systems were evaluated for this task in the TREC Precision Medicine tracks. [7,8,9] We also developed
PRIMROSE [10], a search engine that implements many of the best aspects of precision oncology search. A consistent
weakness in these IR approaches, however, was difficulty dealing with the complex semantics of precision oncology
articles: identifying the exact treatments studied in an article, which types of cancer the treatment applies to, etc. This
task is more consistent with a natural language processing (NLP) information extraction (IE) approach. Therefore, in
this work we report the initial development of an NLP system for extracting five key elements of biomedical articles
for precision oncology: the type(s) of cancer studied, the mutations that were targeted, the specific population it is
limited to, the treatment evaluated, and any available outcome information summarized in the abstract. Because of the
fast-moving nature of the field, we focus on biomedical abstracts instead of full-text articles. Not only are the abstracts
publicly available well before the full text, but many of the latest-breaking developments in precision oncology are
presented at talks in major oncology conferences and only the abstracts for these talks are provided.
To gauge the complexity of this NLP task, we collected a pilot corpus of 250 biomedical abstracts drawn from the
TREC Precision Medicine dataset. The five concept types–CANCER, MUTATION, POPULATION, TREATMENT, and
OUTCOME–were double-annotated and reconciled. Two models based on BERT [11], and specifically the BioBERT [12]
model pre-trained on biomedical text, were evaluated: BioBERTBASE and BioBERTLARGE. The difference between
these models is the number of parameters, in terms of number of layers, hidden units, and attention heads.
∗This project was undertaken during an undergraduate internship at UTHealth-SBMI.
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The remainder of this paper is organized as follows. Section 2 discusses related work in NLP for cancer and precision
medicine. Section 3 describes the methods, including data (§3.1), annotation (§3.2), and automatic concept extraction
(§3.3). Section 4 details the results. Section 5 provides a discussion, including an error analysis, implications, and
directions for future work. Finally, Section 6 concludes the paper.
2 Related Work
Biomedical Literature NLP for Cancer Cancer is one of the more frequently studied aspects of NLP for biomedical
literature articles. Early works such as MedScan [13] employed rule-based systems to extract and interpret information
from MEDLINE abstracts. Chun et al. [14] developed a corpus and extracted relations between prostate cancer and
genes from abstracts using a maximum entropy classifier. Baker et al. developed a corpus for identifying the hall-
marks of cancer from the biomedical literature and proposed a support vector machine (SVM) model [15] and later a
convolutional neural network [16] to automatically classify abstracts. A different take on cancer NLP for the biomedical
literature is the development of literature-based discovery (LBD) tools such as LION LBD [17] to identify implicit links
within the network of literature articles. LION in particular focuses on the molecular biology of cancer. Beyond the
biomedical literature, a tremendous amount of NLP research has been conducted for cancer on other data types. Most
notable among these are electronic health records, for which several review articles exist that overview cancer NLP
for clinical notes. [18,19,20]
Biomedical Literature NLP for Genomics A tremendous amount of NLP work has focused on extracting informa-
tion related to genomics from the literature. Early work includes EDGAR [21] , which identified gene-drug relations
from biomedical abstracts. Libbus et al. [22] identified genes from MEDLINE abstracts based on the Gene Ontol-
ogy [23] for the purpose of linking literature-based data to structured knowledge sources. Work in pharmacogenomics
has required extensive use of NLP to build resources such as the use of SemRep [24] or the construction of the pharma-
cogenomics knowledge base PharmGKB. [25,26,27] In turn, PharmGKB has been utilized as a knowledge base for many
further NLP studies. [28,29,30] Similarly, the PGxCorpus [31] is a manually-annotated corpus for pharmacogenomics–
similar in many ways to our goal here, but their work is not specific to cancer. Finally, more general biomedical
literature NLP has included genomic components, particularly the CRAFT corpus. [32,33]
Biomedical Literature NLP for Precision Oncology There has indeed been some work specific to precision
medicine for NLP within the space of the current work. For instance, Deng et al. [34] classifies abstracts with an
SVM based on whether they focus on cancer penetrance. Bao et al. [35] extends this with a deep learning model. In-
stead of extracting the particular concepts, however, these works focus is simply to classify the entire abstract for use in
downstream meta-analyses. Next, Hughes et al. [36] reviews how to utilize precision oncology NLP specific for breast
cancer. Finally, the TREC Precision Medicine track [7,8,9] is an ongoing information retrieval shared task focusing on
identifying articles relevant to precision oncology. This has inspired the creation of many search engines, including
our own, [10] for clinical decision support in precision oncology. Of the many search engines to participate in the TREC
Precision Medicine track, however, none has successfully integrated biomedical knowledge sources to greatly improve
retrieval performance. We believe this is partly due to the fact that it is difficult to properly link the key aspects of
precision oncology in an abstract to these powerful knowledge bases. Instead, most use of biomedical knowledge in
such search engines is simply to expand synonyms (e.g., through query expansion) which gives at most small boosts to
retrieval performance. Our goal in this paper, then, is to lay the groundwork for improvements in precision oncology
search and knowledge acquisition by identifying the key elements to precision oncology in biomedical abstracts. This
will allow for the downstream linking of these articles with existing biomedical knowledge bases for better semantic
comprehension of the precision oncology scientific landscape.
3 Methods
The high-level study design for this paper follows the standard supervised NLP pipeline: data identification (Sec-
tion 3.1), manual data annotation (Section 3.2), and automatic NLP extraction (Section 3.3). Since this is a pilot study,
our primary goal has been to identify the key barriers to large-scale system development, which is discussed in more
detail in the Discussion (Section 5).
3.1 Data
Since the latest developments of precision oncology research are only publicly available in abstracts, we focus only on
abstract-based annotation and extraction. Compared to biomedical research in general, precision oncology is dispro-
portionately less represented in PubMed Central given its funding structure (less open access, more embargoed journal
articles) and heavy use of abstract presentations for presenting results–which means many of the latest developments
that are so important to capture are not available as full text articles, but only abstracts. We focus on a set of abstracts
known to be relevant to precision oncology by annotating only abstracts judged as relevant in the TREC 2017 Precision
Medicine track [7]. A random selection of 250 abstracts was chosen from those judged relevant during the assessment
process.
3.2 Annotation Process
The 250 abstracts were imported into Brat [37] and double-annotated with the following concept types:
1. CANCER. The type of cancer being studied in the article (e.g., “breast cancer”, “non-small cell lung cancer”,
“mantle cell lymphoma”, “solid tumor”). If the abstract mentions a type of cancer but it is clearly not the cancer
investigated in the study, then it is additionally labeled as a Non-study cancer. If multiple types of cancer are
included in the study, all are annotated.
2. MUTATION. The gene mutation being studied in the article, be it a gene with any mutation (e.g., “KRAS”,
“FGFR2”, “PIK3R1”), a specific variant (e.g., “BRAF V600E”, “KRAS G13D”, “NF2 K322”), or some other
form of genetic mutation (e.g., “CDK4 Amplification”, “PTEN Inactivating”, “EML4-ALK Fusion transcript”).
Similar to cancer type, mutations mentioned in the abstract but not investigated in the study are marked as
Non-study mutations.
3. POPULATION. The specific population in the study (e.g., “Hunan Province in China”, “never or light smokers”,
“adults (> 18 years)”, “European patients”, “no history of chemotherapy for metastatic disease”). As shown
by the examples, this can include age, sex, location, ethnicity, cancer status, etc. Populations mentioned in the
abstract but not investigated in the study are marked as Non-study populations.
4. TREATMENT. The drug used in the study (e.g., “sorafenib”, “abemaciclib”, “trastuzumab”). If the drug was
used as part of a combination, each individual component is annotated separately. If the drug was a comparator
but not directly investigated in the study, then it is marked as a Non-study treatment (this is more common than
Non-study cancers, mutations, and populations).
5. OUTCOME. The result of the study with regards to the success or failure of the treatment. Non-study outcomes
are not annotated. The outcomes are generally a sentence or long phrase describing the overall outcome. E.g.,
• Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the
chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased
amino-transferase concentrations (two [2%] vs 0).
• Treatment with crizotinib results in clinical benefit rate of 85%-90% and a median progression-free sur-
vival of 9-10 months for this molecular subset of patients.
• Although nearly all patients with GIST treated with imatinib experienced adverse events, most events were
mild or moderate in nature.
Additionally, negated concepts were marked as such. While there were negated CANCER annotations (e.g.,
Two annotators (the first author and a biomedically-trained graduate student) labeled each abstract in batches of 25,
reconciling after each batch. Instead of using highly-refined guidelines, the goal of this annotation process was more
exploratory in nature. The concepts were defined as above, but no further. The goal was to identify the range of pos-
sible ways in which the information can be expressed, without too much regard for maximizing inter-rater agreement.
Number of abstracts 250
Average length of abstract (tokens) 278.1
Total concept annotations 4,722
CANCER 1,622
MUTATION 2,293
POPULATION 133
TREATMENT 544
OUTCOME 130
Percent Non-study annotations 1.2%
CANCER 0.9%
MUTATION 0.8%
POPULATION 0.8%
TREATMENT 4.0%
OUTCOME 0.0%
Average concept length (tokens) 3.3
CANCER 2.7
MUTATION 2.3
POPULATION 4.4
TREATMENT 3.0
OUTCOME 28.5
Table 1: Descriptive statistics of the annotated corpus.
Anecdotally, some concepts had more inconsistent agreement throughout the process (notably POPULATION and OUT-
COME), while others had early disagreement that improved over time (such as how to handle acronyms with CANCER
and MUTATION). These issues are ultimately reflected in the automatic extraction scores described in Section 4.
Descriptive statistics of the annotated corpus are provided in Table 1. Example annotations from the corpus are shown
in Figure 1.
3.3 Automatic Extraction
The abstracts were tokenized and split into sentences using spaCy [38]. A BILOU scheme was used for sequence
classification, where B is the first token of a sequence, I an inside token, L the last token, O a token outside any
sequence, and U a single-token concept. So “K - ras and PTEN mutations” would be [B-MUTATION, I-MUTATION,
L-MUTATION, O, U-MUTATION, O]. Non-study concepts were handled by adding a N- before the concept name
(e.g., B-N-TREATMENT).
We follow the standard BERT framework for named entity recognition tasks. Two variants of BioBERT [12] were
evaluated: BioBERTBASE v1.1 and BioBERTLARGE v1.1, which are versions of BERTBASE and BERTLARGE re-
spectively pre-trained on both 1 million PubMed abstracts (note that the BioBERT v1.0 models are pre-trained on
200k PubMed abstracts and 200k PubMed Central full-text articles, but BioBERT v1.1 is only pre-trained on ab-
stracts, though a larger number). As such, BioBERT is an ideal starting point for a transformer-based language model
to use for our task. BioBERTBASE has 12 layers, 768 hidden units per layer, and 12 attention heads per layer (a total
of 110 million parameters); BioBERTLARGE has 24 layers, 1024 hidden units per layer, and 16 attention heads per
layer (a total of 340 million parameters). Generally, the larger BERT variant offers some improved performance, but in
many cases the performance delta is neglible and not worth the additional computational cost. As such, we experiment
with both models to assess whether a larger BERT model would be beneficial in this task.
The data was split 70% for training the BioBERT models, 10% for validation (early stopping), and 20% for testing
(results discussed below). The default BioBERT parameters were used other than a learning rate of 2x10−5, maximum
sequence length of 128, training batch size of 32, validation batch size of 8, and test batch size of 8.
Figure 1: Example annotations
Annotation Precision Recall F1
Overall 60.48 70.73 65.20
CANCER 69.31 78.65 73.68
MUTATION 59.35 69.13 63.87
POPULATION 41.82 42.59 42.20
TREATMENT 47.79 71.05 57.14
OUTCOME 0.0 0.0 0.0
Table 2: Results using BioBERTBASE model.
Annotation Precision Recall F1
Overall 63.79 71.90 67.61
CANCER 70.54 80.06 75.00
MUTATION 61.51 68.78 64.94
POPULATION 56.25 50.00 52.94
TREATMENT 58.59 76.32 66.29
OUTCOME 0.0 0.0 0.0
Table 3: Results using BioBERTLARGE model.
4 Results
The results for the BioBERTBASE and BioBERTLARGE models are provided in Table 2 and Table 3. Not enough
Non-study concepts are present in the test set to merit an evaluation here. We thus focus on boundary extraction and
type classification without the Non-study attribute.
In almost every case, the BioBERTLARGE results outperform the BioBERTBASE results (the lone exception being
MUTATION recall, while neither model successfully extracts any OUTCOME). The differences between BioBERTBASE
and BioBERTLARGE are often several points, including substantial boosts for both POPULATION (+10.74 F1) and
TREATMENT (+9.15 F1). Notably, the improvements from BioBERTBASE to BioBERTLARGE are roughly propor-
tional to the number of available annotations for training, with the most common concept type (MUTATION) receiving
the smallest boost.
For both models, their performance across the different concept types was roughly proportional to the number of
annotations for training. While there were more MUTATION annotations than CANCER annotations, there was a far
greater variety of MUTATION mentions than CANCER mentions, which likely explains why CANCER outperforms
MUTATION in both models by roughly 10 points of F1. TREATMENT is the next most common concept type, and
while for BioBERTBASE this performs 6.73 points of F1 worse than MUTATION, for BioBERTLARGE TREATMENT
actually outperforms MUTATION by 1.35 points of F1. Meanwhile, for both models POPULATION is the second-
worst-performing concept type, while as mentioned neither model correctly identifies a single OUTCOME. The latter
is almost certainly due to the combination of few annotations (130 in the entire corpus) and long, complex nature
of each concept span (28.5 tokens). Clearly, OUTCOME extraction is not an ideal named entity recognition task and
should be handled by a different type of extraction (e.g., sentence classification).
Finally, it is interesting that with the exception of POPULATION for BioBERTLARGE, all concepts have higher recall
than precision. This requires further investigation, but one possibility is that the BERT models are good at identifying
instances very similar to those in the training data, but additionally predict spans with high biomedical similarity that
are nonetheless not one of the annotated concepts.
5 Discussion
This work is an initial feasibility study on the extraction of key variables for precision oncology from biomedical
literature abstracts. We focus on identifying the type of cancer, mutation, population information, treatment, and
outcomes. A small corpus of 250 abstracts was manually annotated, then two BioBERT models were evaluated. While
none of the five concept types performed up to the level one would hope, CANCER performed reasonably well (F1
of 75.00), while MUTATION and TREATMENT showed promise (F1 of 64.94 and 66.29, respectively). POPULATION
performed below a level that is likely usable (F1 of 52.94), while OUTCOME was not successfully extracted at all.
Here, we discuss the successes and shortcomings of this feasibility pilot and what should come next to address the key
problems.
The most obvious need for improvement is the small size of the dataset. Our point of reference for appropriate dataset
sizes is the NCBI Disease Corpus, [39,40] which has 793 abstracts, or roughly three times the size of what is presented
here. BioBERT’s performance on that corpus is an F1 of 89.71, which we can assume is a rough upper bound for
automatic extraction if the corpus was scaled up. We will note, however, that even the CANCER, MUTATION, and
TREATMENT concepts themselves are more diverse than what is in the NCBI Disease Corpus, and the lexical variation
seen with even these concepts is likely greater (especially TREATMENT, see Figure 1), so this would be an ambitious
upper bound. Ultimately, it seems clear that increasing the corpus size would be beneficial.
Regarding the lower-performance concepts, it is likely that POPULATION needs to be refined as a concept, which
would allow it to incorporate pre-defined lexicons. In this study we intentionally did not define this concept narrowly
in order to assess the range of populations mentioned in abstracts. Going forward, however, we can focus on the set of
populations that are critically important to precision oncology. These usually differ from the normal medical notion of
a population. Instead of demographics, in precision oncology the cancer and treatment history are primary populations
of interest (e.g., “treatment-naive” in Figure 1 refers to patients who have not yet undergone chemotherapy). Regarding
OUTCOME, this is clearly an item that is more appropriately tackled as a sentence classifier than via entity extraction.
As can be seen in Figure 1, the OUTCOME sentences have fairly clear features not seen in the other sentences, so it is
likely that a sentence classifier could identify these with relatively high efficacy.
The comparison of BioBERTBASE and BioBERTLARGE is instructive. At the current size of the corpus, the larger
model provides more than sufficient benefit to justify its additional complexity. Perhaps in a larger corpus, the base
model will close the gap. In other works (e.g., Ji et al. [41]), the larger model performed no better than the base model.
These experiments, then, should be revisited with a larger corpus.
Another logical place for improvement is the use of knowledge resources. In this study, we hoped to assess the
performance of BioBERT alone, but future work should incorporate existing knowledge resources such as the NCI
Thesaurus [42] for cancer names and COSMIC [43] for gene mutations. Above, we stated the NCBI Disease Corpus
performance is a good estimate of an upper bound, but the one advantage of focusing exclusively on precision oncology
is that more detailed knowledge resources can be brought to bear: a more specific domain allows us to make domain-
specific assumptions. This could be critical for improving performance, but there is one important note of caution
which also justifies our initial reasoning to evaluate a resource-free approach. Since precision oncology moves quickly
as a field, the lexicon of terms used in papers is oftentimes well ahead of knowledge resources. A new oncogene may
be identified months or years before it is incorporated into the appropriate knowledge base. Over-reliance on these
knowledge sources may increase the NLP performance on the annotated corpus while simultaneously reducing the
model’s ability to recognize the very emerging concepts we are most focused on identifying. Thus, these knowledge
resources cannot be integrated naively, and care should be taken in this process.
A final avenue for improvement focuses on the machine learning aspects. This includes adjusting the tagging scheme–
we used BILOU in this study, but given the variance in concept length (see Table 1) other tagging schemes may be
more appropriate. Not every concept type need use the same tagging scheme, either. E.g., the shorter MUTATION
concepts may utilize a more simple BIO scheme. Additionally, the only form of transfer learning we experimented
with in this paper is the use of the BioBERT model itself, which effectively transfers a language model pre-trained on
large amounts of biomedical text. After the language modeling, but prior to fine-tuning the model on this precision
oncology corpus, other existing datasets may be utilized for transfer learning, such as the NCBI Disease Corpus [39,40]
and PGxCorpus [31]. This would effectively reduce the need to scale up the size of our own manual corpus, though we
do not believe that even with transfer learning the current corpus size is sufficient.
Limitations The data evaluated in this study was taken from the TREC Precision Medicine track, [7] and specifically
the subset of abstracts marked as relevant for one of the topics. As such, it is certainly not representative of the full
array of biomedical literature. This decision was made for annotation convenience–these abstracts were known to
be highly relevant to precision oncology. However, the real bias introduced here is the manual nature in which they
were chosen. Identifying potentially relevant abstracts to annotate via keywords or machine learning would result
in a corpus that is more appropriate, as these methods could be re-applied when using the precision oncology NLP
model on new abstracts. A second limitation is the training of the annotators was intentionally kept minimal so as to
encourage exploration of potential concepts. Also, only one of the two annotators was biomedically trained. We have
discussed the need for additional manual annotation, but this will also need to come with additional training and more
refined guidelines to ensure annotation quality.
6 Conclusion
This work presents a pilot study for NLP information extraction of terms related to precision oncology from biomed-
ical literature abstracts. Five concept types were targeted: CANCER, MUTATION, POPULATION, TREATMENT, and
OUTCOME. A small corpus of 250 abstracts was manually annotated and reconciled. Two BioBERT models were
evaluated for automatic extraction, with the best results ranging in F1 of 75.0 (for CANCER) to a complete inability to
extract OUTCOME information. We finally discussed a set of opportunities for future work to improve these results,
including a larger corpus, use of existing biomedical knowledge resources, and additional transfer learning.
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